Skip to main content
. 2020 Jul;8(14):855. doi: 10.21037/atm-19-4498

Table 3. Overview of within-subject (CVI) and between-subject (CVG) biological variation (BV) estimates and analytical variation (CVA) published for parathyroid hormone (PTH).

Study Gender State of well being Number of subjects Matrix Sampling Assay CVA % (95% CI) CVI % (95% CI) CVG % (95% CI) SCORE
Takahashi et al., 2002 (12) Females Healthy 10 Serum 1 sample/day for 5 days Second-generation PTH assay – 16.4 – C5,7,8,10,11,12,13
Viljoen et al., 2008 (13) Mixed Healthy 20 Plasma 1 sample/week for 5 weeks Immunoassay 3.3 (2.9–3.8)§ 25.3 (21.9–30.0)§ 43.4 (32.4–63.8) § C5,7,8,10,12,13
Ankrah-Tetteh et al., 2008 (14) Mixed Healthy 10 Serum 1 sample/week for 6 weeks Immunoassay 5.0 (3.2–11.0)§ 25.9 (21.3–32.4)§ 23.8 (14.5–44.5) § C7,8,10,13
Gardham et al., 2010 (15) Mixed Healthy 12 Plasma 2 samples/week for 6 weeks Second-generation PTH assay 3.5 (3.2–4.0)§ 19.2 (17.1–21.9) § – C10
Third-generation PTH assay 4.2 (3.8–4.8)§ 23.8 (21.2–27.1) § –
All hemodialysis patients 22 (19 for BV estimation) Second-generation PTH assay 3.6 (3.3–4.0)§ 25.6 (23.3–28.3) § –
Third-generation PTH assay 6.3 (5.8–7.0)§ 30.2 (27.5–33.5) § –
Hemodialysis patients with mean PTH concentration in the tertile 1 7 Second-generation PTH assay 3.7 (3.2–4.4)§ 31.7 (27.4–37.7) § –
Hemodialysis patients with mean PTH concentration in the tertile 2 8 3.4 (2.9–3.9)§ 27.2 (23.7–31.9)§ –
Hemodialysis patients with mean PTH concentration in the tertile 3 7 3.9 (3.4–4.6)§ 4.5 (3.6–5.6)§ –
Hemodialysis patients with mean PTH concentration <300 ng/L 13 3.5 (3.1–4.0)§ 31.2 (28.2–37.3)§ –
Hemodialysis patients with mean PTH concentration ≥300 ng/L 9 3.9 (3.4–4.5)§ 13.9 (12.1–16.2)§ –
Hemodialysis patients who dialyzed in the morning 9 3.5 (3.1–4.0)§ 32.1 (3.2–37.3)§ –
Hemodialysis patients who dialyzed in the afternoon 13 3.7 (3.4–4.2)§ 19.8 (17.7–22.4)§ –
Smith et al., 2012 (16) Mixed Healthy 12 Plasma 1 sample/week for 6 weeks Immunoassay 2.5 (2.2–3.0)§ 20.2 (17.1–24.6)§ 21.8 (14.4–37.6)§ C10,12
Cavalier et al., 2013 (17) Mixed Hemodialysis 17 Serum 2 samples/week for 6 weeks Second-generation PTH assay 2.3 (2.1–2.6)§ 13.8 (12.5–15.4)§ – C5,7,8,10,12,13
Third-generation PTH assay 4.5 (4.1–5.0)§ 14.9 (13.5–16.7)§ –
Lutsey et al., 2016 (18) Mixed Atherosclerosis 160 Serum 2 samples/week for 6 weeks Immunoassay 5.1 (4.1–6.8)§ 16.7 (14.8–18.9)§ 37.9 (33.7–43.0)§ C5,7,8,10,11,13
Schleck et al., 2017 (19) Mixed Healthy 22 Plasma 2 samples on the Mondays, Wednesdays, and Fridays of 2 consecutive weeks Second-generation PTH assay 1.5† (1.4–1.6)§ 19.0 (17.4–20.9)§ – C7,8,10,12,13
Third-generation PTH assay 2.5† (2.3–2.7)§ 24.0 (22.0–26.4)§ –
Serum Second-generation PTH assay 1.6† (1.5–1.8)§ 19.0 (17.4–20.9)§ –
Third-generation PTH assay 2.0 (1.8–2.2)§ 24.0 (22.0–26.4)§ –
Meijers et al., 2017 (20) Mixed Healthy 28 Not specified 1 sample every 4 weeks for 20 weeks Not specified 1.1 (0.8–1.7)§ 16.7 (14.8–19.2)§ 39.8 (31.3–54.3)§ C3,4,8,10
Chronic heart failure 83 Not specified 1 sample every 3 weeks for 9 weeks Not specified 1.1 (0.9–1.5)§ 22.5 (20.3–25.2)§ 49.2 (42.2–58.6)§
Ercan et al., 2019 (21) Mixed Healthy 20 Serum 1 sample/week for 10 weeks Second-generation PTH assay 3.8 (3.3–4.4) 21.1 (19.4–23.2) 24.9 (18.4–37.0) C7,8,10
Men 10 18.5 (15.8–21.5) 26.2 (17.5–48.7)
Women 10 24.0 (20.9–28.2)§ 18.6(11.7–34.4)§
The EuBIVAS study Mixed Healthy 91 Serum 1 sample/week for 10 weeks Third-generation PTH assay 3.3 (3.1–3.4) 14.7 (14.0–15.5) -
Men 38 13.0 (12.1–14.2) 26.8 (21.4–35.1)
Women 53 15.2 (14.3–16.3)
Women <50 years 43 15.5 (14.4–16.7) 27.8 (22.7–36.1)
Women >50 years 10 14.2 (12.3–16.6) 30.8 (21.3–62.3)

†, analytical variation (CVA) with 95% CI calculated by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) biological variation database (10); §, 95% CI calculated by the EFLM biological variation database (10).